Global Giardiasis Treatment Market, By Drug Class (Amebicides, Anthelmintic, Others), Drug Type (Branded, Generic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights Global Giardiasis Treatment Market
The giardiasis treatment market is expected to witness market growth at a rate of 6.80% in the forecast period of 2022 to 2029. Data Bridge Market Research report on giardiasis treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the prevalence of chronic diseases globally is escalating the growth of giardiasis treatment market.
Giardiasis, also known as Beaver Fever, refers to a type of protozoan infection that is caused by Giardia Duodenalis. The protozoan is also known as G. lamblia and G. intestinalis. About 10% of population who are infected by giardiasis tend to show no symptoms. The common symptoms of the disease include abdominal pain, weight loss and diarrhea. This usually occurs due to contaminated food and water.
The rise in water pollution levels across the globe acts as one of the major factors driving the growth of giardiasis treatment market. The increase in the prevalence of the giardiasis among population, especially in children and their parents owning to the fact that nappy changing in children increases the risk of infection accelerate the market growth. The increase in the number of newborn babies in developing countries and consumption of unhygienic water and food and through water sources contaminated with animal and human feces further influence the market. Additionally, surge in healthcare expenditure, development in technology, growth in awareness, lack of sanitation practices and rise in cases of protozoan infections positively affect the giardiasis treatment market. Furthermore, ongoing research activities related to giardiasis treatment and favorable regulatory scenario extend profitable opportunities to the market players in the forecast period of 2022 to 2029.
On the other hand, side effects related to use of anti-protozoan drugs are expected to obstruct the market growth. The ignorance related to treatment of giardiasis is projected to challenge the giardiasis treatment market in the forecast period of 2022-2029.
This giardiasis treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info giardiasis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Giardiasis Treatment Market Scope and Market Size
The giardiasis treatment market is segmented on the basis of drug class, drug type, end-users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drug class, the giardiasis treatment market is segmented into amebicides, anthelmintic and others.
- On the basis of drug type, the giardiasis treatment market is segmented into branded and generic.
- On the basis of end-users, the giardiasis treatment market is segmented into hospitals, homecare, specialty clinics and others.
- On the basis of distribution channel, the giardiasis treatment market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.
Giardiasis Treatment Market Country Level Analysis
The giardiasis treatment market is segmented on the basis of drug class, drug type, end-users and distribution channel.
The countries covered in the global giardiasis treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
Asia-Pacific dominates the giardiasis treatment market due to the presence of the large population within the region. Europe is expected to witness high growth during the forecast period of 2021 to 2028 because of the increase in awareness in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The giardiasis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Giardiasis Treatment Market Share Analysis
The giardiasis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related giardiasis treatment market.
Some of the major players operating in the giardiasis treatment market report are F. Hoffmann-La Roche Ltd, Mylan N.V., Teva Pharmaceuticals Industries Ltd, Hikma Pharmaceuticals PLC, Sun Pharmaceuticals Industries Ltd, Amneal Pharmaceuticals LLC, Merck & Co., Inc., Alkem Labs Ltd, and Cipla Inc., among others.
SKU-